The randomization list (also known as randomization schedule) is a central document in randomized controlled trials that assigns each study participant to a treatment group or treatment sequence before the start of the study. This assignment is carried out according to a predefined, random procedure and forms the operational basis for randomization in a clinical trial. <\/p>\n
The randomization list is typically generated by an independent biostatistician or a specialized randomization system before the first study participant is enrolled in the study. It contains the corresponding treatment assignment (e.g., active drug or placebo, Arm A or Arm B) for each randomization number or patient ID. In blinded studies (single-blind or double-blind design), the randomization list is kept sealed and is exclusively accessible to authorized personnel. <\/p>\n
Depending on the study design, various randomization procedures are used: simple randomization, block randomization (also known as blocked randomization), stratified randomization, or adaptive randomization. In block randomization, participants are assigned in blocks of fixed or variable size to ensure a balanced ratio between treatment groups. In stratified randomization, stratification variables (e.g., gender, center, disease severity) are considered to ensure comparability of groups for important prognostic factors. <\/p>\n
The secure storage of the randomization list is a central element of study integrity. In blinded studies, the treatment assignment must not be known to the principal investigator or the study coordinator as long as blinding is maintained. Only authorized persons \u2013 typically the sponsor or an independent Data Safety Monitoring Board (DSMB) \u2013 have access to the unblinded randomization list. <\/p>\n
Today, the randomization list is predominantly stored in Interactive Response Technology (IRT\/IXRS) systems. These systems electronically manage treatment assignment, control drug logistics, and enable seamless auditability of each assignment. The randomization list is part of the Trial Master File (TMF) and is subject to the Essential Document requirements according to ICH E6(R3). <\/p>\n
In exceptional situations \u2013 particularly in medical emergencies requiring immediate knowledge of the treatment \u2013 emergency unblinding is provided for. The study protocol must define a clear procedure for this: who may unblind, under what circumstances, and how will the unblinding be documented? Every unblinding process must be logged in the system and reported to the sponsor without delay. <\/p>\n
Errors in randomization assignment are considered protocol deviations and must be documented as such in the CRF and the Trial Master File. Serious deviations from the randomization procedure \u2013 such as the allocation of an incorrect investigational product or bypassing the system \u2013 can jeopardize the inclusion of a participant in the per-protocol population and influence statistical analysis. <\/p>\n
The randomization list is subject to strict regulatory requirements. According to ICH E9(R1) and EMA guidelines, the randomization procedure must be fully described in the study protocol. The randomization list itself is an essential document according to ICH E6(R3) and must be available at all times for inspections by authorities such as BfArM, PEI, or EMA. <\/p>\n
After database lock and before statistical analysis, the randomization list is released for unblinding together with the Statistical Analysis Plan (SAP) and the Blind Review Protocol. The sequence \u2013 unblinding only after final database lock \u2013 is regulatory mandated to avoid bias in the analysis. GCP inspections regularly verify whether the actual treatment assignment matches the randomization list. <\/p>\n
The randomization list is the core of the internal validity of a randomized controlled trial. A correctly created, securely stored, and consistently adhered-to randomization list protects the study from selection bias and ensures the comparability of treatment groups. Errors in the management of the randomization list are among the most frequent findings in GCP inspections and can, in extreme cases, lead to the questioning of the entire data basis. <\/p>\n
For full-service CROs and sponsors, the careful planning and implementation of the randomization procedure is a critical step in the study start-up process. The choice between paper-based procedures and modern IRT systems, as well as the definition of stratification variables, must be determined early in the study protocol and coordinated with the ethics committee and the competent authorities. <\/p>\n
Who may view the randomization list before the end of the study?<\/strong><\/p>\n In ongoing blinded studies, the unblinded randomization list may only be viewed by persons who do not have a direct role in the clinical conduct or assessment. Typically, these are the sponsor’s independent biostatistician, the Data Safety Monitoring Board (DSMB), and, in an emergency, authorized medical personnel for emergency unblinding. Every access must be documented in the system’s audit trail. <\/p>\n What happens if the randomization list is compromised?<\/strong><\/p>\n A compromise of the randomization list \u2013 for example, through unauthorized access or accidental disclosure of treatment assignments \u2013 constitutes a serious protocol violation. The sponsor and the principal investigator are obliged to document the incident, inform the ethics committee and the competent authority, and assess the impact on the study. In severe cases, the statistical integrity of the data may be jeopardized, and study termination may become necessary. <\/p>\n How is the randomization list managed in multicenter studies?<\/strong><\/p>\n In multicenter studies, the randomization list is centrally managed, often via an IRT (Interactive Response Technology) system that is accessible to all study sites through a secure interface. Central management ensures that stratification is maintained across all centers and that investigational medication and randomization numbers are assigned consistently. Site-specific randomization lists are only used in exceptional cases and require special precautions to maintain blinding. <\/p>\n The randomization list (also known as randomization schedule) is a central document in randomized controlled trials that assigns each study participant to a treatment group or treatment sequence before the start of the study. This assignment is carried out according to a predefined, random procedure and forms the operational basis for randomization in a clinical […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6757","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6757\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6757"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n